84 related articles for article (PubMed ID: 9290013)
1. ["Killing" of pseudomonas aeruginosa isolated from patients with critical post-operative complications. Effect of various antibiotics].
Delogu G; Iona E; Amati F; Marandola M; Costantini D; Baumgartner IM; Mascellino MT
Ann Ital Chir; 1997; 68(2):219-24. PubMed ID: 9290013
[TBL] [Abstract][Full Text] [Related]
2. [Effect of superinhibitory levels of imipenem and amikacin singly or in combination on Pseudomonas aeruginosa].
Hostacká A
Epidemiol Mikrobiol Imunol; 1997 Dec; 46(4):155-7. PubMed ID: 9471306
[TBL] [Abstract][Full Text] [Related]
3. Clinical, microbiologic, and epidemiologic characteristics of Pseudomonas aeruginosa infections in a University Hospital, Malatya, Turkey.
Yetkin G; Otlu B; Cicek A; Kuzucu C; Durmaz R
Am J Infect Control; 2006 May; 34(4):188-92. PubMed ID: 16679175
[TBL] [Abstract][Full Text] [Related]
4. Postantibiotic effect of imipenem, alone and in combination with amikacin, on Pseudomonas aeruginosa.
Gerçeker AA; Otük G
Chemotherapy; 1995; 41(6):433-6. PubMed ID: 8529433
[TBL] [Abstract][Full Text] [Related]
5. Outer membrane proteins profiles of Pseudomonas aeruginosa after the post-antibiotic effect of imipenem.
Hostacká A; Karelová E
Microbios; 1997; 90(362):45-50. PubMed ID: 9301070
[TBL] [Abstract][Full Text] [Related]
6. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections.
Cao B; Wang H; Sun H; Zhu Y; Chen M
J Hosp Infect; 2004 Jun; 57(2):112-8. PubMed ID: 15183240
[TBL] [Abstract][Full Text] [Related]
7. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program.
Turner PJ
Diagn Microbiol Infect Dis; 2006 Nov; 56(3):341-4. PubMed ID: 17049798
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients.
Harris AD; Smith D; Johnson JA; Bradham DD; Roghmann MC
Clin Infect Dis; 2002 Feb; 34(3):340-5. PubMed ID: 11774081
[TBL] [Abstract][Full Text] [Related]
9. [Four years of monitoring of antibiotic sensitivity rates of Pseudomonas aeruginosa and Acinetobacter baumannii strains isolated from patients in intensive care unit and inpatient clinics].
Alişkan H; Colakoğlu S; Turunç T; Demiroğlu YZ; Erdoğan F; Akin S; Arslan H
Mikrobiyol Bul; 2008 Apr; 42(2):321-9. PubMed ID: 18697430
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
Ong CT; Tessier PR; Li C; Nightingale CH; Nicolau DP
Diagn Microbiol Infect Dis; 2007 Feb; 57(2):153-61. PubMed ID: 16930925
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparative analysis of two case-control studies in hospitalized patients.
Zavascki AP; Cruz RP; Goldani LZ
J Hosp Infect; 2005 Feb; 59(2):96-101. PubMed ID: 15620442
[TBL] [Abstract][Full Text] [Related]
12. [Antibacterial effect of N-formimidoyl-thienamycin in combination with amikacin, cefoxitin and fosfomycin on K. pneumoniae and P. aeruginosa].
Schröter G; Schrettenbrunner A
Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1982 Dec; 253(3):355-7. PubMed ID: 6820589
[No Abstract] [Full Text] [Related]
13. Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa in a tertiary care hospital.
Raja NS; Singh NN
J Microbiol Immunol Infect; 2007 Feb; 40(1):45-9. PubMed ID: 17332906
[TBL] [Abstract][Full Text] [Related]
14. Clinical surveillance of surgical imipenem-resistant Pseudomonas aeruginosa infection in a Japanese hospital.
Sasaki M; Hiyama E; Takesue Y; Kodaira M; Sueda T; Yokoyama T
J Hosp Infect; 2004 Feb; 56(2):111-8. PubMed ID: 15019222
[TBL] [Abstract][Full Text] [Related]
15. Hospital-acquired pneumonia in critically ill patients: factors associated with episodes due to imipenem-resistant organisms.
Leroy O; d'Escrivan T; Devos P; Dubreuil L; Kipnis E; Georges H
Infection; 2005 Jun; 33(3):129-35. PubMed ID: 15940413
[TBL] [Abstract][Full Text] [Related]
16. Antibiotics at sub-inhibitory concentrations and virulence factors of Pseudomonas aeruginosa.
Cipriani P; Trancassini M; Chiossi MR; De Vito D; Filadoro F
New Microbiol; 1998 Jul; 21(3):285-8. PubMed ID: 9699211
[TBL] [Abstract][Full Text] [Related]
17. Nosocomial outbreak by imipenem-resistant metallo-beta-lactamase-producing Pseudomonas aeruginosa in an adult intensive care unit in a Brazilian teaching hospital.
Cezário RC; Duarte De Morais L; Ferreira JC; Costa-Pinto RM; da Costa Darini AL; Gontijo-Filho PP
Enferm Infecc Microbiol Clin; 2009 May; 27(5):269-74. PubMed ID: 19386392
[TBL] [Abstract][Full Text] [Related]
18. [Nosocomial respiratory infection due to an imipenem-resistant Pseudomonas aeruginosa O: 12 strain in a Tunis's neonatal intensive care unit].
Achour W; Abbassi MS; Cherif A; Jabnoun S; Khrouf N; Ben Hassen A
Pathol Biol (Paris); 2006 Dec; 54(10):596-9. PubMed ID: 17030453
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment of Pseudomonas aeruginosa with a sub-MIC of imipenem enhances bactericidal activity of neutrophils.
Sasahara T; Satoh Y; Sekiguchi T; Suzuki K; Irinoda K; Takayama Y; Sakamoto A; Kitasato H; Okamoto R; Inoue M
J Infect Chemother; 2003 Dec; 9(4):297-303. PubMed ID: 14691649
[TBL] [Abstract][Full Text] [Related]
20. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients.
Bjarnsholt T; Jensen PØ; Fiandaca MJ; Pedersen J; Hansen CR; Andersen CB; Pressler T; Givskov M; Høiby N
Pediatr Pulmonol; 2009 Jun; 44(6):547-58. PubMed ID: 19418571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
